Subscribe
Susan Chiappinelli, GSK, second L-R
10 October 2024NewsEuropeMuireann Bolger

GSK: ‘Whoever moves first has UPC advantage’

Value-for-money UPC is worth it says GSK corporate counsel | Court offers alternative to costly US litigation | Head of vaccine patents says UPC offers “strategic plank” in Europe.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Unified Patent Court
Unified Patent Court visualised: Cases, divisions, and classes in charts
12 September 2024   Data visualisations based on the court’s activity from June to August reveal that the use of English is growing, German divisions are dominating, and appeals are creeping up, writes Marisa Woutersen.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Unified Patent Court
Unified Patent Court visualised: Cases, divisions, and classes in charts
12 September 2024   Data visualisations based on the court’s activity from June to August reveal that the use of English is growing, German divisions are dominating, and appeals are creeping up, writes Marisa Woutersen.

More on this story

Unified Patent Court
Unified Patent Court visualised: Cases, divisions, and classes in charts
12 September 2024   Data visualisations based on the court’s activity from June to August reveal that the use of English is growing, German divisions are dominating, and appeals are creeping up, writes Marisa Woutersen.

More features

Novartis shields eye-drop patent at European Patent Office
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages
Judge denies Intellia bid to throw out suit over $100m Regeneron pact